Millions of people with diabetes have no or only limited access to electricity that limits their ability to store insulin according to the recommendations of the insulin manufacturer in general. At the same time, environmental temperatures are increasing in many countries which have a negative impact on the glucose-lowering effect of insulin not stored adequately. Therefore, the availability of heat-stable insulin formulations that do not require constant cooling would be of help for many patients; however, despite this clinical need, apparently not many are in clinical development. This commentary discusses the different aspects and approaches that are of relevance in this context.
PingelMVolundA. Stability of insulin preparations. Diabetes. 1972;21:805-813.
6.
StorvickWOHenryHJ. Effect of storage temperature on stability of commercial insulin preparations. Diabetes. 1968;17(8):499-502. doi:10.2337/diab.17.8.499.
7.
DasAShahMSaraogiI. Molecular aspects of Insulin aggregation and various therapeutic interventions. ACS Bio Med Chem Au. 2022;2(3):205-221. doi:10.1021/acsbiomedchemau.1c00054.
8.
BrangeJHallundOSørensenE. Chemical stability of insulin—5: isolation, characterization and identification of insulin transformation products. Acta Pharm Nord. 1992;4(4):223-232.
9.
BrangeJHavelundSHougaardP. Chemical stability of insulin—2: formation of higher molecular weight transformation products during storage of pharmaceutical preparations. Pharm Res. 1992;9(6):727-734. doi:10.1023/A:1015887001987.
10.
GroenningMFrokjaerSVestergaardB. Formation mechanism of insulin fibrils and structural aspects of the insulin fibrillation process. Curr Protein Pept Sci. 2009;10(5):509-528. doi:10.2174/138920309789352038.
11.
YuYBBriggsKTTarabanMBBrinsonRGMarinoJP. Grand challenges in pharmaceutical research series: ridding the cold chain for biologics. Pharm Res. 2021;38(1):3-7. doi:10.1007/s11095-021-03008-w.
12.
HeinemannLSieberJKulzerB. Connected pens or smart pens: technology needs context [published online ahead of print August 18, 2024]. J Diabetes Sci Technol. doi:10.1177/19322968241274796.
13.
PfütznerARazIBittonG, et al. Improved insulin absorption by means of standardized injection site modulation results in a safer and more efficient prandial insulin treatment: a review of the existing clinical data. J Diabetes Sci Technol. 2015;9(1):116-122. doi:10.1177/1932296814555400.
14.
RiegerCKurzKMueller-HoffmannWGehrBLieblA. New design of a percutaneous port system for continuous intraperitoneal Insulin Infusion. J Diabetes Sci Technol. 2019;13(6):1158-1160. doi:10.1177/1932296819855425.
RichterBBongaertsBMetzendorfMI. Thermal stability and storage of human insulin. Cochrane Database Syst Rev. 2023;11(11):CD015385. doi:10.1002/14651858.CD015385.pub2.
EmamiFVatanaraAParkEJNaDH. Drying technologies for the stability and bioavailability of biopharmaceuticals. Pharmaceutics. 2018;10(3):131. doi:10.3390/pharmaceutics10030131.
SenSAliROnkarA, et al. Synthesis of a highly thermostable insulin by phenylalanine conjugation at B29 Lysine. Commun Chem. 2024;7(1):161. doi: 10.1038/s42004-024-01241-z.
21.
KassabMM. Protein engineering design of thermostable insulin for use in various medication. Int J Health Sci (Egypt). 2024;2(3):126-143. doi:10.21608/ijhegy.2023.203604.1021.
22.
MukherjeeMDasDSarkarJ, et al. Prion-derived tetrapeptide stabilizes thermolabile insulin via conformational trapping. Iscience. 2021;24(6):102573. doi:10.1016/j.isci.2021.102573.
23.
LiJChuMKLuB, et al. Enhancing thermal stability of a highly concentrated insulin formulation with Pluronic F-127 for long-term use in microfabricated implantable devices. Drug Deliv Transl Res. 2017;7(4):529-543. doi:10.1007/s13346-017-0381-8.
24.
YangCLuDLiuZ. How PEGylation enhances the stability and potency of insulin: a molecular dynamics simulation. Biochemistry. 2011;50(13):2585-2593. doi:10.1021/bi101926u.
25.
JiaYFernandezASampathJ. PEGylation of insulin and lysozyme to stabilize against thermal denaturation: a molecular dynamics simulation study. J Phys Chem B. 2023;127(31):6856-6866. doi:10.1021/acs.jpcb.3c01289.
26.
MastrottoFBellatoFAndrettoV, et al. Physical PEGylation to prevent insulin gibrillation. J Pharm Sci. 2020;109(1):900-910. doi:10.1016/j.xphs.2019.10.020.
27.
TorosantucciRKukrerBMeroAVan WinsenMTantipolphanRJiskootW. Plain and mono-pegylated recombinant human insulin exhibit similar stress-induced aggregation profiles. J Pharm Sci. 2011;100(7):2574-2585. doi:10.1002/jps.22523.
28.
LeeJKoJHMansfieldKMNaukaPCBatEMaynardHD. Glucose-responsive trehalose hydrogel for insulin stabilization and delivery. Macromol Biosci. 2018;18(5):e1700372. doi:10.1002/mabi.201700372.
29.
KabotsoDEKSmileyDMayerJP, et al. Addition of sialic acid to insulin confers superior physical properties and bioequivalence. J Med Chem. 2020;63(11):6134-6143. doi:10.1021/acs.jmedchem.0c00266.
30.
Haghighi-PoodehSKurganovBNavidpourLYaghmaeiPEbrahim-HabibiA. Characterization of arginine preventive effect on heat-induced aggregation of insulin. Int J Biol Macromol. 2020;145:1039-1048. doi:10.1016/j.ijbiomac.2019.09.196.
31.
ZhengQLazoND. Mechanistic studies of the inhibition of insulin fibril formation by rosmarinic acid. J Phys Chem B. 2018;122(8):2323-2331. doi:10.1021/acs.jpcb.8b00689.
32.
Haghighi-PoodehSNavidpourLYaghmaeiPEbrahim-HabibiA. Monocyclic phenolic compounds stabilize human insulin and suppress its amorphous aggregation: in vitro and in vivo study. Biochem Biophys Res Commun. 2019;518(2):362-367. doi:10.1016/j.bbrc.2019.08.064.
33.
KalitnikASzefczykMWojciechowskaAW, et al. Cytotoxic Staphylococcus aureus PSMα3 inhibits the aggregation of human insulin in vitro. Phys Chemist Chem Phys. 2024;26(21):15587-15599. doi:10.1039/D4CP00669K.
34.
GliddenMDAldabbaghKPhillipsNB, et al. An ultra-stable single-chain insulin analog resists thermal inactivation and exhibits biological signaling duration equivalent to the native protein. J Biol Chem. 2018;293(1):47-68. doi:10.1074/jbc.M117.808626.
35.
XiongXBlakelyAKarraP, et al. Novel four-disulfide insulin analog with high aggregation stability and potency. Chem Sci. 2020;11(1):195-200. doi:10.1039/c9sc04555d.
36.
VintherTNNorrmanMRibelU, et al. Insulin analog with additional disulfide bond has increased stability and preserved activity. Protein Sci. 2013;22(3):296-305. doi:10.1002/pro.2211.
37.
HubalekFCramerCNHellebergH, et al. Enhanced disulphide bond stability contributes to the once-weekly profile of insulin icodec. Nat Commun. 2024;15(1):6124. doi:10.1038/s41467-024-50477-9.
38.
KjeldsenTBHubalekFHjorringgaardCU, et al. Molecular engineering of insulin Icodec, the first acylated insulin analog for once-weekly administration in humans. J Med Chem. 2021;64(13):8942-8950. doi:10.1021/acs.jmedchem.1c00257.
